Value of serum Aldo-keto reductase family 1 member B10 （AKR1B10） in diagnosis of hepatocellular carcinoma
- VernacularTitle:血清醛酮还原酶家族1成员B10（AKR1B10）对肝细胞癌的诊断价值
- Author:
Yunling DU
1
;
Changjiang SHI
1
;
Fangyuan GAO
2
;
Mengna ZHANG
1
;
Lingling WANG
1
;
Zhuqing ZHANG
1
;
Ying MING
1
;
Shoujun XIE
1
Author Information
- Publication Type:Journal Article
- Keywords: Carcinoma， Hepatocellular; Aldo-Keto Reductase Family 1 Member B10; Alpha-Fetoproteins
- From: Journal of Clinical Hepatology 2025;41(4):684-689
- CountryChina
- Language:Chinese
- Abstract: ObjectiveTo investigate the expression of serum Aldo-keto reductase family 1 member B10 （AKR1B10） in patients with hepatocellular carcinoma （HCC） in northern China， and to provide a new and valuable biomarker for the clinical diagnosis of HCC. MethodsThis study was conducted among 102 patients with HCC， 119 patients with benign liver disease， and 132 patients with other malignant tumors who attended The Affiliated Hospital of Chengde Medical University and 148 healthy individuals who underwent physical examination from May 2020 to May 2024. ELISA and chemiluminescence were used to measure the serum levels of AKR1B10 and alpha-fetoprotein （AFP）. The Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups， and the Kruskal-Wallis H test was used for comparison between three groups and further comparison between two groups； the chi-square test was used for comparison of categorical data between groups. The area under the ROC curve （AUC） was used to assess diagnostic efficiency. ResultsThe expression level of AKR1B10 was 3 053.79 （1 475.67 — 4 605.86） pg/mL in the HCC group， 1 324.42 （659.68 — 2 023.88） pg/mL in the benign liver disease group， 660.68 （377.56 — 2 087.77） pg/mL in the other malignant tumor group， and 318.30 （82.73 — 478.82） pg/mL in the healthy group， with a significant difference between the four groups （H=240.86， P<0.001）， and further comparison between two groups showed that the HCC group had a significantly higher level than the other three groups （all P<0.001）. The ROC curve analysis of the HCC group and the other three groups showed that serum AKR1B10 had an optimal cut-off value of 1 584.97 pg/mL in the diagnosis of HCC， with an AUC of 0.86 （95% confidence interval ［CI］： 0.82 — 0.90）， a sensitivity of 74.3%， and a specificity of 85.2%. Compared with each indicator alone， a combination of AKR1B10 and AFP could improve the sensitivity （81.8%） and specificity （91.4%） of HCC diagnosis. AKR1B10 had an AUC of 0.84 （95%CI： 0.78 — 0.90） in the diagnosis of patients with early- or middle-stage HCC， with a sensitivity of 76.2% and a specificity of 81.2%. AKR1B10 had an AUC of 0.85 （95%CI： 0.77 — 0.92） in the diagnosis of patients with AFP-negative HCC， with a sensitivity of 81.6% and a specificity of 79.9%. ConclusionAKR1B10 is a promising serological marker for the diagnosis of HCC， and a combination of AKR1B10 and AFP can improve the detection rate of HCC patients in northern China， especially those with early- or middle-stage HCC and AFP-negative HCC.
